Abstract: Disclosed are a method and apparatus for sharing information. A particular embodiment of the method comprises: in response to detecting that a user selects article information from a preset candidate item information set, adding the selected article information to a target article information set; detecting whether the user executes a sharing operation with regard to the target article information set; and in response to detecting that the user has executed the sharing operation with regard to the target article information set, sending the target article information set to an object indicated by the sharing operation. According to the embodiment, the flexibility of information sharing is improved.

Abstract: The present invention relates to methods and compositions for treating a subject with a condition selected from: i) an on-going cytokine storm, ii) acute respiratory distress syndrome (ARDS), and/or iii) acute lung injury (ALI), using a composition comprising ?-glucocerebrosidase, or a vector encoding ?-glucocerebrosidase. In certain embodiments, the condition is caused by COVID-19 virus infection or other viral infection.

Abstract: Provided herein are compositions, systems, kits, and methods for treating IL-17a related diseases and conditions using an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein.

Abstract: Disclosed by the present disclosure are a method and apparatus for displaying product comment information, an electronic device and a storage medium.

Abstract: Provided herein non-human transgenic animals comprising a genome that: i) under-expresses, or is inducible to under-express, Hu Antigen R (HuR) in at least some neurons of said transgenic animal; ii) does not express HuR, or is inducible to not express HuR, in at least some neurons of said transgenic animal; or iii) does not express functional HuR, or is inducible to not express functional HuR in at least some neurons of said transgenic animal, as well as methods of screening drugs and therapies (e.g., useful in treating ALS) using such animals.

Abstract: An azazinoindazole derivative represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, a prodrug thereof, a solvate thereof or a hydrate thereof are presented. The described compound may be used as a 5-HT3 receptor modulator. Experiments have proven that the compound of the preparation example has a strong affinity to 5-HT3 receptors, and has high activity as a modulator of 5-HT3 receptors. The compound may be used to prepare a drug for treating irritable bowel syndrome, nausea, vomiting, gastroenteritis, gastric dysfunction, diarrhea, pain, carcinoid syndrome, drug addiction and other diseases.

Abstract: A method includes receiving, by a first node on a first port of the first node, a first packet from a second node; and when the first packet carries a first flag, avoid selecting, by the first node and when selecting a clock source, a clock source corresponding to the first port, where the first flag indicates that time synchronization of the second node is uncertain.

Abstract: Provided is a solar tile structure, and the solar tile structure includes a solar cell module and a tile. The tile has a first side surface and a second side surface arranged oppositely in a thickness direction of the tile, the first side surface is provided with an embedding groove, and the solar cell module is embedded in the embedding groove. The tile is provided with a disassembly hole, and the disassembly hole is configured to enable the solar cell module to be detached from the embedding groove.

Abstract: Provided herein are compositions, systems, kits, and methods for treating IL-17a related diseases and conditions using an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein.

Abstract: Provided herein are compositions, systems, and methods for detecting and treating IL-17 and/or IL-13 related conditions, such as asthma, autoimmune diseases, and cancer. In some embodiments, methods, compositions, and systems are provided for detecting elevated protein or RNA levels of IL-17 (and/or IL-13) and a second marker selected from: SAA, LCN2, and YKL-40, and treating the subject with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor. In other embodiments, methods, compositions, and systems are provided for detecting a biomarker in a sample from a subject that has been treated with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor, where the biomarker is SAA, LCN2, or YKL-40, and where at least one action is performed, such as identifying elevated levels of the biomarker in the biological sample and treating the subject with an IL-17 (or IL-13) inhibitor and/or IL-17 (or IL-13) receptor inhibitor.

Abstract: The present invention relates to methods and compositions for treating a subject with a condition selected from: i) an on-going cytokine storm, ii) acute respiratory distress syndrome (ARDS), and/or iii) acute lung injury (ALI), using a composition comprising ?-glucocerebrosidase, or a vector encoding ?-glucocerebrosidase. In certain embodiments, the condition is caused by COVID-19 virus infection or other viral infection.

Abstract: The present invention describes a method of treating a steroid-resistant disease or condition such as severe asthma in a subject by administering a therapeutically effective amount of an anthocyanin and a corticosteroid to a subject in need thereof.

Abstract: Provided herein are compositions, systems, kits, and methods for treating IL-17a related diseases and conditions using an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein.

Abstract: Provided herein non-human transgenic animals comprising a genome that: i) under-expresses, or is inducible to under-express, Hu Antigen R (HuR) in at least some neurons of said transgenic animal; ii) does not express HuR, or is inducible to not express HuR, in at least some neurons of said transgenic animal; or iii) does not express functional HuR, or is inducible to not express functional HuR in at least some neurons of said transgenic animal, as well as methods of screening drugs and therapies (e.g., useful in treating ALS) using such animals.

Abstract: The present invention discloses a highly efficient and intelligent drug and parenteral nutrition product automatic collation and reversion device, which comprises a feeding conveyor belt, a discharging conveyor belt, a returning conveyer belt and computer; and in the junction of the feeding conveyor belt, the discharging conveyor belt and the returning conveyer belt is provided an inspection module. In the present invention, drug dispatch is configured to be done just as a production line, by providing a weighing scale to measure the weight of drugs, and four cameras to assist in identifying drugs to check whether correct drugs are dispatched, and in case that any errors detected, the wrong drugs will be sent back to the original position for inspection, which improves efficiency and accuracy of drug dispatch and reduces manpower cost.

Abstract: The present invention describes compounds according to formula I: and compounds according to formula II: and additional related flavonoid compounds, as well as the use of the compounds in methods for the prevention or treatment of IL-17A-mediated disease in a subject.

Abstract: Provided herein are compositions, systems, and methods for detecting and treating IL-17 and/or IL-13 related conditions, such as asthma, autoimmune diseases, and cancer. In some embodiments, methods, compositions, and systems are provided for detecting elevated protein or RNA levels of IL-17 (and/or IL-13) and a second marker selected from: SAA, LCN2, and YKL-40, and treating the subject with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor. In other embodiments, methods, compositions, and systems are provided for detecting a biomarker in a sample from a subject that has been treated with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor, where the biomarker is SAA, LCN2, or YKL-40, and where at least one action is performed, such as identifying elevated levels of the biomarker in the biological sample and treating the subject with an IL-17 (or IL-13) inhibitor and/or IL-17 (or IL-13) receptor inhibitor.

Abstract: A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the ?C helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma.